Evidence map›Paper›PMID 31922537›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Evaluation of Phylogenetic Methods for Inferring the Direction of Human Immunodeficiency Virus (HIV) Transmission: HIV Prevention Trials Network (HPTN) 052.

Yinfeng Zhang, Chris Wymant, Oliver Laeyendecker, M Kathryn Grabowski, Matthew Hall, Sarah Hudelson, Estelle Piwowar-Manning, Marybeth McCauley, Theresa Gamble, Mina C Hosseinipour and 13 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Molecular source attribution.PLoS computational biology · 2022
    Article
  13. Article
  14. Using phylogenetics to infer HIV-1 transmission direction between known transmission pairs.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  15. Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Yinfeng ZhangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Chris WymantBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Oliver LaeyendeckerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
M Kathryn GrabowskiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Matthew HallBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Sarah HudelsonDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Estelle Piwowar-ManningDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Marybeth McCauleyHIV Prevention Trials Network Leadership and Operations Center, FHI, Washington, District of Columbia, USA.
Theresa GambleHIV Prevention Trials Network Leadership and Operations Center, FHI, Durham, North Carolina, USA.
Mina C HosseinipourDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Nagalingeswaran KumarasamyChennai Antiviral Research and Treatment Clinical Research Site, Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India.
James G HakimDepartment of Medicine, University of Zimbabwe, Harare, Zimbabwe.
Johnstone KumwendaCollege of Medicine-Johns Hopkins Project, Blantyre, Malawi.
Lisa A MillsUS Centers for Disease Control and Prevention, HIV Research Branch, Kisumu, Kenya.
Breno R SantosDepartment of Infectious Diseases, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas -Fiocruz, Rio de Janeiro, Brazil.
Jose H PilottoHospital Geral de Nova Iguacu and Laboratorio de AIDS e Imunologia Molecular-Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro, Brazil.
Suwat ChariyalertsakResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
Joseph MakhemaBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Ying Q ChenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Myron S CohenDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Christophe FraserBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Susan H EshlemanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
The Malawi Clinical Trials UnitUM1AI069518 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JACKY M JENNINGS, TAHA E TAHA · 2012 to 2026
$43.8M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)U01AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI GRINSZTEJN, BEATRIZ · 2008 to 2011
$14.0M
Revealing women's hidden role as critical components of HIV transmission networks in Rakai, Uganda: an interdisciplinary approachK01AI125086 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRABOWSKI, MARY KATHRYN · 2016 to 2020
$638k
NIAID NIH HHS K01 AI125086NIAID NIH HHS P30 AI094189NIAID NIH HHS U01 AI069476NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069476NIAID NIH HHS UM1 AI069518
6 · The paper itself

Abstract

backgroundPhylogenetic analysis can be used to assess human immunodeficiency virus (HIV) transmission in populations. We inferred the direction of HIV transmission using whole-genome HIV sequences from couples with known linked infection and known transmission direction.

methodsComplete next-generation sequencing (NGS) data were obtained for 105 unique index-partner sample pairs from 32 couples enrolled in the HIV Prevention Trials Network (HPTN) 052 study (up to 2 samples/person). Index samples were obtained up to 5.5 years before partner infection; partner samples were obtained near the time of seroconversion. The bioinformatics method, phyloscanner, was used to infer transmission direction. Analyses were performed using samples from individual sample pairs, samples from all couples (1 sample/person; group analysis), and all available samples (multisample group analysis). Analysis was also performed using NGS data from defined regions of the HIV genome (gag, pol, env).

resultsUsing whole-genome NGS data, transmission direction was inferred correctly (index to partner) for 98 of 105 (93.3%) of the individual sample pairs, 99 of 105 (94.3%) sample pairs using group analysis, and 31 of the 32 couples (96.9%) using multisample group analysis. There were no cases where the incorrect transmission direction (partner to index) was inferred. The accuracy of the method was higher with greater time between index and partner sample collection. Pol region sequences performed better than env or gag sequences for inferring transmission direction.

conclusionsWe demonstrate the potential of a phylogenetic method to infer the direction of HIV transmission between 2 individuals using whole-genome and pol NGS data.

Indexed as

HIV-1HIV InfectionsHumansPhylogenydirection of transmissionHIVHPTN 052next-generation sequencingphylogenetic analysis

Identifiers

PMID31922537
PMCPMC7823077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.